Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Pharmacodynamics
- Sponsors Sunovion Pharmaceuticals
- 29 Nov 2017 According to a Sunovion Pharmaceuticals media release, data of the trial will be presented at the American Epilepsy Society (AES) Annual Meeting 2017.
- 10 Jun 2017 Biomarkers information updated
- 01 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.